Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Internal Medicine | Pharmacy | Journal

Back to Journal Articles

Allopurinol Has Little Benefit in Cardiac Syndrome X

Last Updated: November 17, 2017.

Allopurinol does not appear to improve exercise capacity or peripheral endothelial or coronary function in patients with cardiac syndrome X, according to a study published online Oct. 28 in Cardiovascular Therapeutics.

FRIDAY, Nov. 17, 2017 (HealthDay News) -- Allopurinol does not appear to improve exercise capacity or peripheral endothelial or coronary function in patients with cardiac syndrome X, according to a study published online Oct. 28 in Cardiovascular Therapeutics.

Tiong Keng Lim, M.D., from National Heart Centre Singapore, and colleagues randomized 19 patients with cardiac syndrome X (mean age 59 years) to six weeks of treatment with either allopurinol (600mg/day) or placebo. Patients were crossed over to the other study arm after a four-week washout period.

The researchers found that allopurinol significantly reduced serum uric acid levels versus placebo. There was no significant difference in maximum exercise time, coronary flow reserve, or flow-mediated vasodilatation of the brachial artery between the allopurinol and placebo groups. However, there was a trend toward allopurinol reducing serum B-type natriuretic peptide compared with placebo (P = 0.07).

"In patients with cardiac syndrome X, high dose allopurinol did not improve exercise capacity, coronary or peripheral endothelial function," conclude the authors.

Abstract
Full Text (subscription or payment may be required)


Previous: Psychosocial Benefit Seen With Probiotic, Peanut Oral Immunotx Next: First-Line Metformin Use for DM Up; Sulfonylurea Use Down

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: